Developing new treatments to combat bacterial resistance using biopharmaceuticals
Official title: Preclinical Services for Antibacterial Resistance Biopharmaceutical Product Development
Funded at University of Saskatchewan · NIH-10934790 · Data updated 2026-11-12
This study is working on new treatments to help fight stubborn bacterial infections that don't respond to regular antibiotics, so patients can have better options for getting better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Saskatchewan NIH-funded |
| Lab location | 1 site (Saskatoon, Canada) |
| Project start | September 8, 2023 |
| Project end | September 7, 2030 |
| Funding year | 2023 |
| Award (this year) | $1,023 |
| NIH project number | 75N93023D00013-0-759302300001-1 |
| Project ID | NIH-10934790 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria.
✕Less likely to help
Patients with infections that are not caused by bacterial pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.
What this research studies
This research focuses on the preclinical development of innovative biopharmaceutical products aimed at addressing bacterial drug resistance. It involves creating and evaluating various biological materials, including small interfering RNA (siRNA) and monoclonal antibodies, to enhance treatment options for infectious diseases. The approach includes product development planning, assay development, and regulatory support to ensure effective translation of these therapies into clinical settings. Patients may benefit from new therapies that could be more effective against resistant bacterial infections.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments that effectively combat bacterial infections resistant to current therapies.
How similar studies have gone: Previous research has shown promise in developing biopharmaceuticals for infectious diseases, indicating that this approach has potential for success.
Where this research is happening
-
University of Saskatchewan
Saskatoon, Canada Active
Related research
Other NIH-funded projects on the same topics.
-
Developing models to understand infectious diseases.
This study is working on building models that mimic infectious diseases to help scientists learn how they work and find better treatments, which could lead to improved options for patients dealing with these illnesses.
-
Developing models to understand infectious diseases.
This study is all about building models that mimic infectious diseases so researchers can learn how they work and find better treatments, which could help patients like you in the future.
-
Developing models to understand infectious diseases.
This study is all about building models that mimic infectious diseases so researchers can learn how they work and find better treatments, which could help patients like you in the future.
-
Developing new biopharmaceutical products for infectious diseases
This study is working on improving the way new medicines, like antibodies and proteins, are developed to help treat infectious diseases, so that patients can have better and more effective treatment options.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.